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A B S T R A C T
A proper understanding of P-gp mediated transport (functionality) at the blood-brain barrier (BBB) and beyond
is needed to interpret, understand and predict pharmacokinetic (PK)- pharmacodynamic (PD) relationships of
CNS drugs that are substrates of P-gp, especially since P-gp functionality may be diﬀerent in diﬀerent conditions.
Often, P-gp expression is taken as a biomarker of transporter functionality. The aim of our study was to in-
vestigate whether brain capillary protein expression of P-gp is associated with changes in P-gp mediated drug
eﬄux at the BBB.
Status Epilepticus (SE) was induced by kainate in male rats. During 3–5weeks post SE, hippocampal P-gp
expression was determined using immunohistochemistry, while BBB P-gp functionality was assessed by micro-
dialysis of quinidine, in absence and presence of the P-gp blocker tariquidar. The data were analyzed using Non-
linear Mixed Eﬀect Modeling implemented in NONMEM.
Following SE, changes in brain capillary P-gp expression were observed. However, no relation between BBB
P-gp protein expression and BBB P-gp mediated drug eﬄux was found. This warrants a critical view on the
interpretation of reported changes in BBB P-gp expression as a biomarker of BBB P-gp functionality.
1. Introduction
Adequate drug distribution to the target site is a prerequisite for
drug-target interaction and thereby drug eﬀects. Apart from passive
diﬀusion, active drug transport can have an important impact on drug
distribution over diﬀerent body compartments. Active transport de-
pends on transporter functionality, which is condition dependent. (Erdö
et al., 2017; Kervezee et al., 2014). This indicates that a proper un-
derstanding of transporter functionality is needed to interpret, under-
stand and predict pharmacokinetic (PK)- pharmacodynamics (PD) re-
lationships in diﬀerent conditions. (de Lange et al., 2017).
Drug distribution into the brain is determined by both drug - and
blood-brain barrier (BBB) properties (Yamamoto et al., 2018). The BBB
contains many active transporters, and for any drug being a substrate of
one of these transporters, the rate as well as extent of drug distribution
into the brain can be inﬂuenced by active transport processes. P-gly-
coprotein is considered the most important eﬄux transporter at the
BBB, having many drugs as substrates. Many studies have been devoted
to understanding the impact of P-gp mediated BBB eﬄux in brain dis-
tribution of its substrates. Moreover, P-gp may be present not only at
the BBB but also at brain parenchymal cells (Lee et al., 2001).
An in vivo technique that can be used to determine rate and extent
of drug brain distribution is Positron Emission Tomography (PET). PET
measures the total activity of a tracer, incorporated in the drug right
before injection into the living subject. This technique has many ad-
vantages, such as being non-invasive (therefore can be used in humans)
and providing time as well as spatial resolution, however, one of its
disadvantages is that it cannot distinguish between bound and unbound
drugs. This makes that BBB transport parameters cannot be speciﬁcally
measured, although it is often reported like that. Another in vivo
technique is intracerebral microdialysis (de Lange et al., 2017). This
technique is minimally invasive and its use in humans is therefore
highly restricted, but can be used in animals to provide highly valuable
data. It uses a probe being implanted into a selected location in the
brain that has a semipermeable membrane by which molecules small
enough to pass the membrane can be taken with the perfusion ﬂuid.
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The ﬂuid can be collected in intervals, and these samples can be ana-
lyzed on its drug content. It thereby provides unbound drug con-
centration-time proﬁles that can be related to unbound plasma con-
centration-time proﬁles to give BBB speciﬁc information on rate and
extent of BBB transport, including active transporter functionality.
(Westerhout et al., 2013).
One of the important brain diseases that has been associated with
changes in P-gp functionality is pharmacoresistant epilepsy, as in epi-
leptogenic brain tissue of patients with pharmacoresistant epilepsy, an
increased expression of P-glycoprotein (P-gp) at the BBB has been found
(Dombrowski et al., 2001; Marchi et al., 2016, 2004; Tishler et al.,
1995). To investigate the potential role of P-gp in pharmacoresistant
epilepsy, animals models that make use of induced kainite, pilocarpine,
or electrically induced Status Epilepticus (SE) have been frequently
employed, measuring P-gp gene mRNA expression and/or P-gp protein
expression, and variable results on post-SE changes in P-gp expression
at 24 h, 48 h, 7 days and/or 14 days post SE have been reported
(Bankstahl and Löscher, 2008; Kuteykin-Teplyakov et al., 2009; Seegers
et al., 2002; Van Vliet et al., 2004; Volk and Loscher, 2005; Volk et al.,
2004).
To assess P-gp functionality, Syvänen et al. studied potential
changes in BBB P-gp function in kainate induced SE rats, 7 days post SE,
using PET experiments with (R)- C-11 Verapamil, and microdialysis
experiments with quinidine, and BBB P-gp expression by im-
munohistochemistry in brain capillaries at 7 days post-SE (Syvänen
et al., 2011; Syvänen et al., 2012b). These studies did not reveal any
signiﬁcant diﬀerence in brain P-gp function nor expression at 7 days
post-SE compared to saline-treated (control) animals at this time point.
Taken together, studies on the relationship between time after SE, P-
gp expression at the BBB and P-gp function at the BBB are inconsistent.
The variable results may have been caused by diﬀerences in the
methods used to induce SE, diﬀerences in protocols to measure P-gp
expression, diﬀerent techniques used to determine P-gp function, and
inter-individual variability in severity of subsequent development of
spontaneous seizures. Therefore it is of interest to investigate the time-
course of P-gp expression following SE, in conjunction with BBB P-gp
function.
In this study SE was induced in rats either using the intraperitoneal
or intrahippocampal injection of kainite. The time-course of hippo-
campal brain capillary P-gp protein expression was assessed by im-
munohistochemistry. Changes in P-gp expression following in-
trahippocampal injection of kainite induced SE were most pronounced
and related to changes in BBB hippocampal P-gp function in the same
individual rats by intracerebral microdialysis using quinidine and
mathematical modeling, for a period up to 5 weeks post SE. Data were
analyzed by Non-linear Mixed Eﬀect modeling (NONMEM), and the
relation between brain capillary P-gp expression and P-gp functionality
was assessed.
2. Methods
2.1. Animals
Adult male Sprague-Dawley rats (Harlan, Horst, The Netherlands)
weighing 200–249 g on arrival were used throughout the study. After
arrival, all animals were housed in groups of 5 to 6 per Makrolon type
three cage for 7–14 days (Animal Facilities, Gorlaeus Laboratories,
Leiden, the Netherlands) prior to the start of experiments. They were
kept under standard environmental conditions (ambient temperature
21 ± 1 °C; humidity 60%; 12/12 h light/dark cycle in which white
lights were switched on at 8:00 AM, in the presence of background
noise, and undergoing daily handling), with ad libitum access to food
(RM3 (E) DU, Special Diets Services B.V., Witham, Essex, England) and
acidiﬁed water.
Between surgery and experiments, the animals were kept in-
dividually in cages for 7 days to recover from the surgical procedures.
Animal procedures were performed in accordance with Dutch laws on
animal experimentation. All experiments were approved by the Ethics
Committee for Animal Experiments of Leiden University (approval
numbers UDEC08180 and UDEC10057).
Table 1
Diﬀerent sites of kainite injections to induce Status Epilepticus (SE) in rats (intraperitoneal (IP) or intra-hippocampal (IH), and the number of rats included to
determine brain capillary P-gp protein expression, and BBB P-gp mediated transport at the diﬀerent days post SE.
Description Group A Group B Group C
IP kainate treatment Microdialysis surgery
followed by unilateral IH
kainate treatment
Microdialysis surgery followed by unilateral IH kainate
treatment and bilateral microdialysis experiments
Description for number or rats (n)
Total of control rats and all kainate-
treated rats
n= 40 n=17 n=35
Kainate-treated rats that reached scale
IV or V seizures and were included
in the P-gp expression analysis
n= 34 n=13 n=31
Euthanasia
(days after control-treatment)
Day 1 (n=1), day 2 (n=1), 4 (n= 1),
day 7 (n= 1), day 10 (n= 1), day 14
(n= 1), day 21 (n=1), day 28 (n= 1)
Total n= 8.
Day 2 (n= 1),day 7 (n= 1),
day 22 (n= 1), Total n= 3
Day 2 (n= 1),day 7 (n= 1), day 22 (n= 1), Total n= 3
Euthanasia
(days after kainate-treatment)
Day 1 (n=3); day 2 (n=5); day 3
(n= 1); day 4 (n= 2); day 7 (n= 5); day
10 (n= 2); 14 (n= 4); day 21 (n=2), day
28 (n= 2) Total n= 26
Day 2 (n= 4), day 7
(n= 5), day 22 (n= 4),
Total n=13
Day 2 (n=1), day 3 (n=1), day 4 (n= 1), day 5
(n= 1), day 6 (n= 2), day 7 (n=1), day 9 (n= 1), day
10 (n= 1), day 11 (n= 1), day 12 (n= 1), day 13
(n= 1), day 14 (n=1), day 15 (n= 1), day 16 (n= 1),
day 18 (n= 1), day 20 (n=1), day 21 (n= 1), day 22
(n= 1), day 23 (n=1), day 24 (n= 1), day 25 (n= 1),
day 26 (n= 1, day 27 (n= 1), day 28 (n=1), day 30
(n= 1), day 31 (n=1), day 32 (n= 1), day 33 (n= 1),
day 34 (n= 1), day 36 (n=1). Total n=31
Euthanasia (days after kainite treatment
for rats that had successful
microdialysis experiments)
day 2 (n= 1), day 3 (n= 1), day 4 (n= 1), day 5
(n= 1), day 6 (n= 2), day 7 (n=1), day 9 (n= 1), day
10 (n= 1), day 12 (n= 1), day 13 (n= 1), day 14
(n= 1), day 16 (n=1), day 22 (n= 1), day 25 (n= 1),
day 27 (n= 1), day 30 (n=1), day 32 (n= 1), day 34
(n= 1). Total n=19
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2.2. Experimental Study Designs
Table 1 shows the diﬀerent sites of kainite injections to induce
Status Epilepticus (SE) in rats (intraperitoneal (IP) or intra-hippo-
campal (IH), and the number of rats included to determine brain ca-
pillary P-gp protein expression and BBB P-gp mediated transport at the
diﬀerent days post SE.
2.2.1. Intraperitoneal (IP) Kainate Treatment (Group A)
Kainic acid (Sigma-Aldrich, Zwijndrecht, the Netherlands) was dis-
solved in saline and administered as repetitive intraperitoneal (IP
mode) injections to rats until full-blown seizures were observed. First,
an initial IP kainate dose of 10mg/kg (2mL/kg, in saline) was ad-
ministered followed by 5mg/kg (1mL/kg) IP every 30–60min until
stage IV or V seizures according to Racine's scale occurred. (Racine,
1972), or when a total amount of 30mg/kg kainate was reached. Ve-
hicle, i.e. saline only, was administered IP to 8 control rats.
Most rats treated with IP injections of kainate displayed stage IV or
V seizures (26 out of 32 rats, Table 1, Group A). Typically three kainate
injections were needed, i.e. 20mg/kg and SE was usually reached
within 20min after the last injection. Rats usually displayed seizures for
1–2 h. The seizures were not interrupted by any anti-epileptic drug. The
rats that did not reach stage IV were discarded (n=3), and some rats
did not recover (n=3). Two rats died as a result of the kainate treat-
ment and one animal was taken out of the experiment and euthanized
as it did not recover properly from the treatment. All other rats were
included in the P-gp expression analysis. Rats were observed daily after
treatment to monitor their recovery and development of spontaneous
seizures. The IP treated rats, were euthanized by decapitation between
1 and 28 days after SE.
2.2.2. Unilateral Intrahippocampal (IH) Kainate Treatment (Group B)
In another group of rats intrahippocampal injection of kainate was
performed.
Before surgery each rat received a subcutaneous injection (0.1 mL)
of both the antibiotic Ampicillan 20% (Alfasan Nederland B.V.
Woerden) and the analgesic Temgesic 0.3mg/mL (Schering-Plough,
Utrecht). All cannulas and electrodes that were to be implanted had
undergone 24-h decontamination before use and during surgery eye
cream was applied to the eyes to prevent dehydration.
2.2.2.1. Surgery. Each rat was anaesthetized with isoﬂurane
(Pharmachemie BV, Haarlem, The Netherlands), and the animals' core
temperature was maintained at 37 °C. The rats were placed in a
stereotaxic frame. An incision on the top of the head was made using
a scalpel. The skin was retracted and lidocaine was applied to the skull
that was scraped, cleaned, and allowed to dry. Two small holes were
drilled into the skull for insertion of the microdialysis guides (CMA/
Microdialysis AB, Stockholm, Sweden) at the following co-ordinates
relative to bregma: AP -5.6, L 4.6 and L - 4.6. Three additional holes
were drilled for support screws as anchor points for the cement. The
guides with dummy probes were inserted into the brain to a depth of
−5.2mm and ﬁxed to the skull using dental cement.
2.2.2.2. Unilateral Intrahippocampal Kainate Treatment. After one week
of recovery, the dummy probe was removed from the guide cannula and
a customized injection probe, consisting of a modiﬁed CMA12 probe
(CMA, Solna, Sweden with the tip cut by a laser to a length of 0.50mm
and a OD of 0.030mm, was inserted. Kainic acid was dissolved (2 μg/
μL) in minimal microdialysis perfusion solution (mPF; containing
140.3 mM sodium, 2.7mM potassium, 1.2mM calcium, 1.0 mM
magnesium and 147.7 mM chloride) and injected to 46 rats,
unilaterally into the left hippocampus (IH) via the modiﬁed CMA12
probe at a constant infusion of 0.1 μL/min for 10min resulting in a total
administered kainate dose of 1 μg. Vehicle, i.e. the minimal perfusion
ﬂuid, was administered according to the same procedure to control rats.
The injection probe was carefully removed and replaced by the dummy
probe approximately 20min after stopping the kainate (n=14) or
vehicle (n=2) infusion. Each animal was observed for at least 2 h after
the start of the infusion to score the severity according to Racine's scale.
Only the rats that reached scale IV or V seizures were included in the
analysis, and one rat died.
To assess P-gp expression IH kainate treated rats were euthanized by
decapitation, at day 2 (n= 4), 7 (n=5) and 22 (n= 4) days after SE
after kainate injection, and in total 3 for the controls at day 2 (n=1),
day 7 (n=1) and day 22 (n=1) (Table 1, Group B).
2.2.3. Unilateral Intrahippocampal (IH) Kainate Treatment (Group C)
In another group of rats the intrahippocampal (IH) injection of
kainate was performed in the left hippocampus while the right hippo-
campus served as control. Bilateral microdialysis experiments were
performed at 1–34 days post SE in individual rats.
2.2.3.1. Surgery. Each rat was anaesthetized with isoﬂurane
(Pharmachemie BV, Haarlem, The Netherlands), and the animals' core
temperature was maintained at 37 °C. The rats received two cannulas.
To obtain blood samples, 3 cm of ID 0.28mm cannula (SIMS Portex
LTD, England) was inserted into the femoral artery, connected to 16 cm
of ID 0.58mm cannula (Portex Fine Bore polythene tubing Smiths
Industries, Kent England).
For drug administration and blood sampling, 4 cm of ID 0.58mm
cannulas were inserted in the femoral vein and artery respectively, and
connected to 16 cm of ID 0.58mm cannula. Both cannulas were led
subcutaneously to the back of the head where it was secured with a
rubber ring. The cannulas were ﬁlled with FPEP to prevent clotting
until the experiment.
Subsequently, the rats were placed in a stereotaxic frame and, like
in group B, an incision on the top of the head was made using a scalpel.
The skin was retracted and lidocaine was applied to the skull that was
scraped, cleaned, and allowed to dry. Two small holes were drilled into
the skull for insertion of the microdialysis guides (CMA/Microdialysis
AB, Stockholm, Sweden) at the following co-ordinates relative to
bregma: AP -5.6, L 4.6 and L - 4.6. Three additional holes were drilled
for support screws as anchor points for the cement. The guides with
dummy probes were inserted into the brain to a depth of−5.2 mm and
ﬁxed to the skull using dental cement.
2.2.3.2. Microdialysis Experiments. At 24 h before the start of the
experiments the microdialysis dummies were replaced by
microdialysis probes (CMA12). At the day of the experiment, the
microdialysis tubing (1.2 μL/100mm FEP-tubing CMA/Microdialysis
AB, Stockholm, Sweden) was connected with tubing adapters (CMA/
Microdialysis, Stockholm, Sweden) to the microdialysis probe's inlet
and outlet. Microdialysis perfusion ﬂuid was prepared according to
Moghaddam et al. (Moghaddam and Bunney, 1989). Microdialysis vials
were pre-weighed and placed in a cooled (4 °C) fraction collector
(Univentor 820 Microsampler, Antec, Netherlands) to collect the
microdialysate samples. Microdialysis probes were continuously
ﬂushed with mPF (2 μL/min, Bee-Hive, Bioanalytical Systems Inc. W-
Lafayette, USA) and samples were collected before and during
quinidine infusion: the ﬁrst sample was taken 1 h prior to infusion of
quinidine. Subsequently samples were collected at 20min intervals at
1 h until 3 h after the start of quinidine infusion. After sample
collection, vials were weighed to determine the actual probe
perfusion rate. Sample series with regular perfusion rates between 1.9
and 2.1 μL/min (i.e. a maximal deviation of 5%) were included in data
analysis. Samples were stored at −20 °C.
At t=0min the IV-infusion of quinidine (Sigma-Aldrich,
Zwijndrecht, The Netherlands) was started according to a regimen to
readily achieve plasma steady-state concentrations with the following
infusion rates: From 0 to 25min at 30 μL/min; from 25 to 60min at
15 μL/min; and from 60 to 140min at 10 μL/min, infused through the
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catheter in the femoral vein. On the basis of previous experiments (data
not shown) at 140min 90% of the steady-state concentration of qui-
nidine was expected, and at that time 15mg/kg Tariquidar (Xenova
Group PLC, Cambridge, England, or API Services Inc. Westford, USA),
was administered during 10min. During the next 10min the quinidine
infusion was resumed, at a rate of 30 μL/min and from 160min on-
wards it was 10 μL/min, to be stopped at 300min. The total quinidine
dose was 15mg/kg/5 h.
During the experiment 10 blood samples of 200 μL were taken from
the cannula in the femoral artery. The sampling was distributed over
7 h. The blood sample volume taken (200 μL) was replaced by the same
volume of heparinized saline to sustain the circulating volume and to
prevent clogging of the line.
At termination of the experiment the animals were euthanized with
an intravenous overdose injection of Nembutal (1 mL). Following de-
capitation the brains were removed, rinsed, immediately embedded in
Tissue-Tec (Sakura Finitek Europe, Zoeterwoude, The Netherlands) and
snap frozen with liquid nitrogen to be stored at −80 °C.
2.3. Quantiﬁcation of Quinidine in Plasma, Dialysates and Brain Tissue
For the HPLC analysis, quinidine was dissolved in methanol and
diluted with water to a concentration of 100 μg/mL. This stock solution
was further diluted in water (plasma and brain analysis) or perfusion
ﬂuid (microdialysate analysis) to construct calibration curves for qui-
nidine analysis.
Quinidine was measured using HPLC with ﬂuorescence detection. A
LC10-ADVP HPLC pump (Shimadzu,'s-Hertogenbosch, the Netherlands)
and an Altima C-18 150×4.6mm column (Grace Altech, Breda, the
Netherlands) was used. The mobile phase consisted of acetonitrile and
phosphate buﬀer (25mM) with triethyl-amine (10mM) at a pH of 2.3 in
a ratio of 17:83 (v/v) and 14/86 (v/v) for microdialysis and plasma
samples, respectively, at a ﬂow rate of 1mL/min. Detection was per-
formed using a Jasco FP-1920 ﬂuorescence detector (Jasco, de Meern,
the Netherlands) set at 488 nm for excitation and 512 nm for emission.
Injection was performed using a Waters 717 autosampler (Waters,
Etten-Leur, the Netherlands). The injection volume was 20 μL. Data
acquisition was performed using Empower Software (Waters, Etten-
Leur, the Netherlands).
Microdialysate was injected directly, without any pretreatment, and
measured. For plasma analysis, 50 μL of the internal standard quinine
(Sigma Aldrich, Zwijndrecht, the Netherlands) in a concentration of
500 ng/mL was added to 20 μL plasma sample. After homogenization
with 200 μL of borate buﬀer pH 10, 5mL of methyl tert-butyl ether was
added. After vortexing, centrifugation, and freezing of the aqueous
layer, the organic phase was evaporated to dryness. The extracts were
reconstituted in 100 μL of mobile phase and centrifuged at 4000×g
during 5min. The clean plasma extracts were injected using a mobile
phase with an acetonitrile/buﬀer ratio of 1:6. Calibration was per-
formed using 20 μL aliquots of quinidine in concentrations of 5, 10, 20,
50, 100, 200, 500, 1000, 2000 and 5000 ng/mL, which were added to
20 μL of blank plasma.
Variability (CV %) of the quantiﬁcation of quinidine in plasma was
below the 15% level. The precision and accuracy of quinidine mea-
surements in microdialysates were< 10%. Limit of quantiﬁcation was
5 ng/mL for plasma, 20 ng/mL for brain, and 1 ng/mL for micro-
dialysate samples.
On the basis of microdialysis experimental quality criteria (perfu-
sion ﬂow deviation not larger than 5% from the intended 2 μL/min) and
analytical criteria (blank microdialysis concentrations< 0.1 ng/ml), 14
rats were excluded from data analysis.
In vivo recovery was determined by retrodialysis (in vivo loss) and
was found to be 24 ± 5.8%, independent of quinidine concentration
and tariquidar treatment (Syvänen et al., 2012b). It was assumed that in
vivo loss would equal in vivo gain. All microdialysis data were cor-
rected for in vivo recovery to estimate brain extracellular ﬂuid (brai-
nECF) concentrations.
Fig. 1. Example of rat hippocampal brain capillary P-gp expression staining (50×).
Arrows serve as a few examples of this staining.
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2.4. Immunohistology
2.4.1. Brain Capillary P-gp Protein Expression Staining in Brain Slices
A Leica CM 1900 cryostat, at a temperature between −16
and− 18 °C, was used to slice the brains into coronal 30 μm sections.
Series of 6 slices were mounted on SuperFrostPlus glass slides capturing
−2.56mm, −3.14mm, −3.30mm, −3.60mm, −3.80mm,
−4.30mm relative to bregma respectively per brain and stored at
−20 °C.
A immunohistochemistry staining protocol based on the use of 3,3-
diaminobenzidine as chromogen to speciﬁcally stain brain capillary P-
gp was applied, and P-gp expression was quantiﬁed as P-gp labelled
area as previously published (Volk and Loscher, 2005; Syvänen et al.,
2011; Syvänen et al., 2012b). In short, for each brain tissue slice the
staining of P-gp protein was quantiﬁed in duplicate as & P-gp labelled
area and these values were averaged per animal per slice location. Brain
sections from all animals were stained simultaneously per group to
obtain comparable staining. Fig. 1 shows an example of P-gp staining in
brain capillaries.
2.5. Pharmacometric Analysis
Analysis of quinidine pharmacokinetic data as obtained in group C
was performed using Nonlinear mixed-eﬀects (NLME) modeling im-
plemented in NONMEM VII (GloboMax LLC, Hanover, MD, USA).
NLME modeling provides a good statistics-based solution for modeling
data to a model that accounts for both ﬁxed eﬀects (group parameters
assumed to be constant each time data is collected) and random eﬀects
(sample-dependent random variables). It is particularly useful in set-
tings where repeated measurements are made on the same statistical
units (longitudinal study), or where measurements are made on clusters
of related statistical units. Because of their advantage in dealing with
missing values, mixed eﬀects models are often preferred over more
traditional approaches such as repeated measures ANOVA.
2.5.1. Quinidine Pharmacokinetics in Plasma and Brain Extracellular Fluid
Quinidine pharmacokinetic (PK) proﬁles in plasma and brain ex-
tracellular ﬂuid (brainECF), including inhibitory eﬀect of tariquidar on
P-gp transport function, was analyzed by systematic comparison of
multiple possible PK models to ﬁnd the model that described the ob-
tained data best. Data from all rats were processed simultaneously. The
subroutine ADVAN 6 and ﬁrst-order conditional estimation with in-
teraction were used throughout the modeling procedure. Model selec-
tion was based on the objective function value (OFV) with the lowest
value corresponding to the best model. For nested models, OFV re-
ductions of 3.83, 6.63 and 10.83 units correspond to improved ﬁts at
p < 0.05, p < 0.01 and p < 0.001 levels, respectively. Also, para-
meter estimates and their relative standard errors, residual error values,
goodness-of-ﬁt plots, and visually predictive check (VPC) were con-
sidered for model selection. During those analyses, software Xpose 4
(Jonsson and Karlsson, 1998). implemented in R 2.15.2 (The R foun-
dation for Statistical Computing) accessed from Census (Wilkins, 2005)
was used to assess the model performance. For example, predicted
concentrations were plotted against measured concentrations and
conditional weighted residuals (Hooker et al., 2007) were calculated
and plotted against time and concentration.
The inter-individual variation of a parameter was described by the
exponential variance model:
= ⋅θ θ ηexp( )i pop i (1)
where θi is the parameter in the ith animal, θpop the parameter in a
typical animal and ηi the inter-animal variability, which is assumed to
be normally distributed around zero with a standard deviation ω. Eq.
(2) provides a means to distinguish the parameter value for the ith
animal from the typical value predicted from the regression model.
Inter-individual variation was investigated for all parameters, but
incorporated only for those parameters for which it signiﬁcantly im-
proved the model (p < 0.01, OFV reduction of 6.63 units). Perfor-
mance of the population pharmacokinetic model was evaluated using
500 additional bootstrap replicates (re-sampling with replacement) of
the data by ﬁtting the ﬁnal model to them.
The pharmacokinetic (PK) quinidine model was constructed in two
steps. In the ﬁrst step, a PK model for quinidine plasma concentrations
was developed. A two compartment model was chosen based on lit-
erature (Sugihara et al., 1993; Watari et al., 1989). Obtained plasma
quinidine PK parameters were ﬁxed, and then used for the analysis of
brainECF quinidine concentrations as a second step. To describe the
inhibitory eﬀect of tariquidar on P-gp, plasma tariquidar PK was
modeled assuming a one compartment model. Tariquidar plasma con-
centration data were taken from literature (Bankstahl and Löscher,
2008; Syvänen et al., 2011).
Obtained PK parameters of tariquidar (CL: 0.29 ± 0.024 L/h, V:
15 ± 0.18 L) were used to describe the inhibition of BBB P-gp function.
For this calculation of tariquidar PK parameters, the pooled data
method was applied since available plasma tariquidar PK data from
literature were an average of pooled individual animals.
Afterwards, rat brain hemisphere (kainate versus vehicle treatment)
and epilepsy severity stage IV or V, were deﬁned as covariates to study
their eﬀects on the parameter estimates. Covariate analysis was per-
formed based on the following equation;
= ⋅ ⋅θ θ η θexp( )i pop i arcov (2)
where θCOVAR described the inﬂuence of kainate treatment or epilepsy
stage on parameter estimate θpop. This model described the brain PK
proﬁle of quinidine including the data obtained during and after the
start of the tariquidar infusion that led to inhibition of P-gp function at
the BBB (CL31Pgp) well.
A stepwise forward addition and backward deletion approach was
applied to test the signiﬁcance (p < 0.01) for covariate inclusion. The
residual variability was described with proportional error models for
each compartment.
Ultimately, based on the above-mentioned criteria, the model dis-
played in Fig. S1 was able to describe the data best. In this model the
inﬂuence of tariquidar on brainECF concentration of quinidine was
described using an inhibitory indirect eﬀect model as follows;
⎜ ⎟= ⋅⎛
⎝
−
⋅
+
⎞
⎠
CL Pgp C CL Pgp
I C
IC C
31 ( ) 31 1TQD
TQD
TQD
max
50 (3)
where CTQD indicates tariquidar plasma concentration and CL31Pgp
(CTQD) (or shortly CL31Pgp′) indicates P-gp mediated quinidine eﬄux
transport (quinidine clearance) from brainECF to plasma in the pre-
sence of tariquidar, respectively. Maximal inhibition of P-gp by tar-
iquidar (Imax) was set to 1. The concentration that would inhibit P-gp
for 50% (IC50) was taken form literature, (80 nM) (Mistry et al., 2001).
3. Results
3.1. Brain Capillary P-gp Expression
3.1.1. IP Kainate Treatment - Group A
It was found that the time course of changes in hippocampal brain
capillary P-gp protein expression following SE by IP kainate (Fig. 2)
showed an increase followed by a decrease. No diﬀerence between
kainate and control rat hippocampus could be found.
3.1.2. IH Kainate Treatment- Group B
Of all rats of group B, brain capillary P-gp protein expression was
investigated at 2 (n= 4), 7 (n= 5) and 22 days (n= 4) post IH kainate
induced SE and controls at day 2 (n= 1), day 7 (n=1) and day 22
(n= 1) (Fig. 3). P-gp expression had a pattern with increase followed
by a decrease, similar to group A, but with higher values of P-gp
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expression. This trend was mostly pronounced for the kainate treated
hippocampus. No such changes were seen in the controls. As the
changes in brain capillary protein P-gp expression were higher in group
B following IH compared to than in group A following IP kainate in-
jection, IH kainite injection was considered best suited for further in-
vestigation on the time-course relation between BBB P-gp expression
and BBB P-gp function using microdialysis.
3.1.3. IH Kainate Treatment and Microdialysis Experiments - Group C
Results of P-gp expression in the rats of group C are shown in Fig. 4.
The brain capillary P-gp protein expression as a function of post SE days
is shown for both left (kainate injection) and left (control injection)
hippocampal areas. Brain capillary P-gp expression increased to max-
imum levels around 7–14 days and then declined over the next 3 weeks.
In contrast to group B, in group C there was no signiﬁcant diﬀerence in
brain capillary P-gp protein expression between the left and right hip-
pocampus. This indicates that the presence of the microdialysis with
induction of SE makes that brain capillary P-gp expression in both
hippocampi show similar patterns. As diﬀerences levels of P-gp ex-
pressions were found over time, the comparison with BBB P-gp func-
tionality could still be made.
3.2. Pharmacokinetics of Quinidine
3.2.1. Plasma Pharmacokinetics
Plasma concentrations of quinidine were obtained as a function of
time (Fig. 5a). The infusion scheme used for the intravenous adminis-
tration of quinidine led, within minutes, to concentrations very close to
steady state, and TQD apparently did not aﬀect the plasma concentra-
tions of quinidine.
3.2.2. Bilateral Hippocampal Microdialysis
In parallel to the serial blood sampling, bilateral microdialysis
sampling was performed. Microdialysis data were obtained from both
the left (kainate treated) and right (control treated) hemisphere. The
quinidine brainECF concentration-time proﬁles are shown in Fig. 5b.
No diﬀerences in quinidine brainECF concentrations were found be-
tween kainate treated and control hippocampus. Upon administration
of tariquidar, a substantial increase in the brainECF quinidine con-
centrations in both hippocampi was observed, indicating successful
blocking of BBB P-gp functionality, i.e. a decrease in P-gp mediated
eﬄux of quinidine.
3.3. Pharmacometric Analysis of BBB P-gp Expression & P-gp Functionality
3.3.1. P-gp Mediated Transport at the BBB
Plasma and brainECF PK proﬁles of quinidine, respectively before
and after tariquidar administration (Fig. 5), were described well by the
proposed quinidine brain distribution model (Fig. S1). The resulting
model parameters are shown in Table 2, together with their inter-in-
dividual variability (η) and residual error. For the brainECF PK of
quinidine (Fig. 5), covariate analysis did not reveal a diﬀerence be-
tween kainate-treated and control hippocampus. However, a clear in-
ﬂuence of P-gp blockage by tariquidar was demonstrated.
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Fig. 2. Hippocampal brain capillary P-gp expression (% P-gp labelled area), in
controls (at virtual time point −5 days) and IP kainite induced SE rats, at dif-
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Fig. 3. Hippocampal brain capillary P-gp expression (% P-gp labelled area), in
controls and IH kainate induced SE rats, at diﬀerent post SE days.
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IH kainate induced SE in treated hippocampus (black diamonds) and control
hippocampus (open diamonds) at diﬀerent days following SE, of rats that un-
derwent bilateral hippocampal microdialysis experiments.
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3.3.2. Relationship Between P-gp Expression and P-gp Functionality
For the purpose of the present study, the diﬀerences in brain ca-
pillary P-gp protein expression between individual animals at diﬀerent
time points after SE were suﬃciently large to establish whether there a
correlation would exist between brain capillary P-gp protein expression
and function. Individual estimates of P-gp function at the BBB
(CL31Pgp) were based on the microdialysis and plasma data of each
individual rat in absence (CLP31gp) and presence of the P-gp inhibitor
tariquidar (CL31Pgp′). P-gp expression was measured ex-vivo in the
same rat. The individual corresponding values for brain capillary P-gp
protein expression and function for each rat are shown in Fig. 6. No
correlation between these two parameters was observed.
4. Discussion
A proper understanding of P-gp mediated transport (functionality)
at the BBB is needed to interpret, understand and predict pharmaco-
kinetic (PK)- pharmacodynamics (PD) relationships CNS drugs that are
substrates of P-gp, especially since P-gp functionality may be diﬀerent
in diﬀerent conditions. (de Lange et al., 2017). An important condition
in which potential changes in P-gp functionality may occur is phar-
macoresistant epilepsy, and many investigations have used rat Status
Epilepticus (SE) models of temporal lobe epilepsy to investigate such
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Fig. 5. Pharmacokinetics of quinidine in A) plasma and B) brainECF of kainate treated hippocampus (black diamonds) and control hippocampus (open diamonds).
Quinidine was administered as a combination of a fast and slow infusion (see Material and Methods), and tariquidar was administered around 110min.
Table 2
Pharmacokinetic modeling parameter values. Results of NLME modeling of
pharmacokinetic data obtained for group C. Parameter estimates of plasma and
brain pharmacokinetics of quinidine from the original dataset and from 500
bootstrap replicates. CL1, Q2, CL13, CL31Pgp, and CL31 are the clearances
from plasma, intercompartmental clearance between central and peripheral
compartment, passive transport from plasma to brain, P-gp mediated transport
from brain to plasma, and passive transport from brain to plasma, respectively.
V1, V2, and V3 are the volume of distribution in central plasma, peripheral
tissue, and brain ECF. V3 was ﬁxed to its physiological volume (145 μL for each
left and right brain ECF; Westerhout et al., 2012). Tariquidar plasma pharma-
cokinetics is described by CL5 (clearance from plasma) and V5 (central volume
of distribution).
Original
mean
SE Bootstrap
median
Percentile
2.5%
Percentile 95%
Parameter values
Cl1 (L/H) 3.68 0.56 3.45 0.56 4.46
V1 (L) 0.19 0.06 0.21 0.08 0.39
Q2 (L/H) 22.3 4.9 20.9 12.1 34.7
V2 (L) 12.5 1.9 13.0 9.9 29.1
CL13 (μL/
H)
8.2 1.8 8.0 5.4 11.8
CL31Pgp
(μL/H)
29.1 6.5 27.9 17.5 41.7
CL31 (μL/
H)
7.6 2.2 7.2 3.7 12.1
Imax 1 Fix
V3 (mL) 0.145 Fix
IC50 (ng/
ML)
25 Fix
V5 (L) 15 Fix
Cl5 (L/H) 0.29 Fix
Inter-individual variability
CL1 0.419 0.214 0.405 0.10 3.42
Q2 0.410 0.252 0.466 0.084 1.20
CL13Pgp 0.45 0.11 0.45 0.25 0.66
CL31 0.94 0.37 0.96 0.39 1.88
Residual error
CMT1 PROP 0.098 0.024 0.095 0.055 0.154
CMT3 KA+
PROP
0.108 0.045 0.109 0.034 0.227
CMT4 KA-
PROP
0.148 0.073 0.144 0.039 0.501
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Fig. 6. BBB P-gp expression (% P-gp labelled area) versus BBB P-gp function
(CL31Pgp) for each individual rat of group C. Black diamonds= kainate treated
hippocampus, open diamonds= control hippocampus. The trendlines indicate
a lack of correlation.
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potential changes in which often P-gp expression (mRNA, protein) has
been used as a biomarker of P-gp transporter functionality. However,
data on P-gp expression and P-gp function that have been reported,
were not directly comparable, as diﬀerent SE models, diﬀerent timings
after SE, and diﬀerent techniques were used.
In the present investigation the relation between brain capillary P-
gp expression and P-gp mediated transport at the BBB was investigated
in the same animal, and no such relationship was found.
4.1. Brain Capillary P-gp Expression
P-gp expression at the BBB was investigated over a period of
~5weeks post SE, induced following IP administration of kainate
(group A) or IH administration (group B and C). In all groups brain
capillary P-gp protein expression changed over time, which was most
pronounced after IH administration of kainate (group B). In group B
diﬀerences were found between P-gp expression at the treated and
nontreated side at day 7, while in group C (with microdialysis) no time-
dependent diﬀerences were found; both hippocampi showed changes in
P-gp expression. This indicated that the control hippocampus in an
individual rat could not serve as the side where no changes in P-gp
expression would occur. However, the relation between P-gp expression
and P-gp functionality could still be investigated.
4.2. P-gp Mediated Transport (P-gp Functionality) at the BBB
Changes in brain capillary P-gp protein expression were the highest
in the IH treated rats (group B) and this model was therefore best
suited to assess the relationship between P-gp expression and func-
tionality, the latter by using quinidine BBB transport in absence and
presence of tariquidar (group C). At diﬀerent days after induction on
SE, bilateral microdialysis experiments using were performed in the
kainate treated and control hippocampus of individual rats. It was
found that quinidine brainECF concentrations were similar in both
hippocampi. Blockage of P-gp by tariquidar led to a substantial (~5-
fold) increase in brainECF quinidine concentrations, in both hippo-
campal brain regions. P-gp mediated eﬄux transport was calculated
using a mathematical model of quinidine brain distribution with tar-
iquidar co-administration as a covariate.
4.3. Relationship Between P-gp Expression and P-gp Functionality
As brain capillary P-gp protein expression was assessed after the
microdialysis experiments, a direct relationship between P-gp expres-
sion and mediated transport at the BBB could be directly investigated
for each individual rat. We used well-established techniques and pro-
tocols for determining BBB speciﬁc P-gp expression (Volk and Loscher,
2005; Syvänen et al., 2011) and BBB speciﬁc P-gp function (Syvänen
et al., 2012a, 2012b; Westerhout et al., 2013). Also, it has been shown
that BBB transport of quinidine decreases when P-gp is upregulated
(Chan et al., 2013).
This leaves the lack between BBB P-gp expression and function as
demonstrated in this study to be compared with apparent contradicting
ﬁndings reported in literature (Bauer et al., 2014; Feldmann et al.,
2013; Jing et al., 2010; Micuda et al., 2008; Ransohoﬀ et al., 2007;
Uchida et al., 2014). In diﬀerent pharmacoresistant epilepsy rat models,
radioactive labelled P-gp substrates were used as a PET ligands ([11C]
verapamil and [11C]quinidine as strong P-gp substrates, and [11C]ﬂu-
mazenil and 5HT1A-receptor antagonist [18F]MPPF as weak P-gp sub-
strates (Bankstahl et al., 2011; Bartmann et al., 2010; Syvänen et al.,
2011; Syvänen et al., 2012a; Syvänen et al., 2013). Most of these studies
have shown diﬀerences in P-gp function between post SE rats and
controls in brain distribution of these PET ligands (Bankstahl et al.,
2011; Syvänen et al., 2011; Syvänen et al., 2013; Bartmann et al., 2010;
Syvänen et al., 2012a; Müllauer et al., 2012) including the eﬀect of P-gp
inhibition.
However, PET measurements reﬂect tracer activities, which (at
best) reﬂect total brain concentrations of the tracer. Because BBB
transport is driven by the diﬀerence in the unbound concentrations at
either side of the BBB (De Lange et al., 1997; Hammarlund-Udenaes
et al., 1997) it is impossible to determine BBB speciﬁc transport and
therewith BBB speciﬁc P-gp function by PET. So, a diﬀerence in total
brain activity of a P-gp substrate tracer between kainate and control
rats detected by PET may not necessarily indicate changes in BBB P-gp,
because it can also reﬂect changes in intra-brain distribution by changes
in P-gp at the level of brain cells that may occur as well (Gibson et al.,
2012; Lee et al., 2001; Ronaldson et al., 2008; Zhang et al., 1999). This
has been demonstrated in a microdialysis study by Syvänen et al.; in
this study, pre-administration of tariquidar resulted in an 7.2 fold in-
crease of brainECF concentrations of quinidine, while total brain con-
centrations increased 40-fold, 7 days post SE induction by kainate
(Syvänen et al., 2012b). Thus, as PET studies cannot discriminate be-
tween changes in P-gp function at the BBB and that at the level of brain
cells, our data are not in contrast with these previous ﬁndings per se, as
we have speciﬁcally measured P-gp function at the BBB level.
Then, in another study by van Vliet et al., P-gp expression in brains
of post-SE rats was found to be 2-fold and 1,5 fold higher in the tem-
poral hippocampus and para-hippocampal cortex, respectively, with
corresponding total brain phenytoin concentrations being decreased by
30% and 20% (van Vliet et al., 2007). As in this study total brain
concentrations were measured, it cannot be concluded that lowered
brain concentrations of phenytoin resulted from increased BBB P-gp
functionality, as this was not measured, while also P-gp expression and
functionality measurements used in this study were not speciﬁc for
BBB.
Finally, in an elegant study of Uchida et al., reconstructed P-gp/
mdr1a functions were integrated with unbound fractions of verapamil
in plasma and brain to reconstruct brain distribution (total brain-
plasma concentration ratio, Kp) for a variety of epilepsy mice models
(Uchida et al., 2014). In that manner they found that reconstructed
Kpuu brain values for verapamil were changed in the diﬀerent mice
models of epilepsy. It should be noted however, that these studies used
isolated brain capillaries for determining the P-gp protein expression in
brain capillaries. Furthermore, the unbound brain concentrations were
estimated indirectly by the brain slide method, as naïve brain slices of
the diﬀerent mice epilepsy models incubated with verapamil for 6 h. In
our study we assessed P-gp functionality in vivo, with individual rat P-
gp expression as obtained within the same hippocampus. Thus, it seems
that the existence of a relation between BBB P-gp expression and
functionality is as least depending on the methodologies used.
4.4. Concluding Remarks
It should be realized that we need speciﬁc data for a proper un-
derstanding of P-gp mediated transport (functionality) at the BBB and
beyond, to understand and predict pharmacokinetic (PK)- pharmaco-
dynamic (PD) relationships of CNS drugs that are substrates of P-gp,
especially since changes in P-gp functionality may be observed in dis-
ease conditions, and may also be brain location dependent.
While many studies report on P-gp expression/functionality at the
BBB, in the majority of those, no explicit distinction is made between P-
gp expression or functionality at the level of the BBB and those at the
level of the brain parenchymal cells. In the current study the direct in
vivo relationship between brain capillary P-gp protein expression and
functionality in epileptic kainate treated and control rats was studied
directly, within the same animal, and no such relationship was found.
Therefore, it seems that brain capillary P-gp functionality does not
necessarily reﬂect BBB P-gp expression. The study of Uchida et al. was
the only study in which BBB speciﬁc P-gp expression and functionality
was investigated and their conclusion was that p-gp expression and P-
gp functionality at the BBB was related (Uchida et al., 2014). Thus, the
existence or absence of such relationship seems to depend at least on
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methodologies used, and on the animal and type of model that has been
used to investigate such relationships. Altogether, it warrants a critical
view on the interpretation of reported changes in (supposedly) BBB P-
gp expression as a biomarker of P-gp functionality.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ejps.2018.08.022.
Competing Interests
None of the authors has any competing interests.
Acknowledgements
This manuscript deals with combining microdialysis experimental
data and advanced mathematical modeling and is dedicated to Prof Dr
Hartmut Derendorf, who is an expert in microdialysis, and pharmaco-
kinetic/pharmacodynamic modeling.
Furthermore, the authors are grateful for the ﬁnancial support of
Foundation Epilepsy Institutions the Netherlands (SEIN) and the EU 7th
Framework Programme EURIPIDES (FP7-under grant agreement n°
201380), and the PKPD modeling platform 2 (2012–2017). Finally, the
work of Dr. N. Doorenweert and Dr. M. Labots for executing the mi-
crodialysis experiments, and P-gp staining, is highly appreciated.
References
Bankstahl, J.P., Löscher, W., 2008. Resistance to antiepileptic drugs and expression of P-
glycoprotein in two rat models of status epilepticus. Epilepsy Res. 82, 72–87. https://
doi.org/10.1016/j.eplepsyres.2008.07.007.
Bankstahl, J.P., Bankstahl, M., Kuntner, C., Stanek, J., Wanek, T., Meier, M., Ding, X.-Q.,
Muller, M., Langer, O., Loscher, W., 2011. A novel positron emission tomography
imaging protocol identiﬁes seizure-induced regional overactivity of P-glycoprotein at
the blood-brain barrier. J. Neurosci. 31, 8803–8811. https://doi.org/10.1523/
JNEUROSCI.6616-10.2011.
Bartmann, H., Fuest, C., La Fougere, C., Xiong, G., Just, T., Schlichtiger, J., Winter, P.,
Böning, G., Wängler, B., Pekcec, A., Soerensen, J., Bartenstein, P., Cumming, P.,
Potschka, H., 2010. Imaging of P-glycoprotein-mediated pharmacoresistance in the
hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy.
Epilepsia 51, 1780–1790. https://doi.org/10.1111/j.1528-1167.2010.02671.x.
Bauer, M., Karch, R., Zeitlinger, M., Liu, J., Koepp, M.J., Asselin, M.C., Sisodiya, S.M.,
Hainfellner, J.A., Wadsak, W., Mitterhauser, M., Müller, M., Pataraia, E., Langer, O.,
2014. In vivo P-glycoprotein function before and after epilepsy surgery. Neurology
83, 1326–1331. https://doi.org/10.1212/WNL.0000000000000858.
Chan, G.N.Y., Patel, R., Cummins, C.L., Bendayan, R., 2013. Induction of P-glycoprotein
by antiretroviral drugs in human brain microvessel endothelial cells. Antimicrob.
Agents Chemother. 57, 4481–4488. https://doi.org/10.1128/AAC.00486-13.
De Lange, E.C.M., Danhof, M., De Boer, A.G., Breimer, D.D., 1997. Methodological con-
siderations of intracerebral microdialysis in pharmacokinetic studies on drug trans-
port across the blood-brain barrier. Brain Res. Rev. 25. https://doi.org/10.1016/
S0165-0173(97)00014-3.
de Lange, E.C.M., van den Brink, W., Yamamoto, Y., de Witte, W.E.A., Wong, Y.C., 2017.
Novel CNS drug discovery and development approach: model-based integration to
predict neuro-pharmacokinetics and pharmacodynamics. Expert Opin. Drug
Discovery 1–12. https://doi.org/10.1080/17460441.2017.1380623.
Dombrowski, S.M., Desai, S.Y., Marroni, M., Cucullo, L., Goodrich, K., Bingaman, W.,
Mayberg, M.R., Bengez, L., Janigro, D., 2001. Overexpression of multiple drug re-
sistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia
42, 1501–1506. https://doi.org/10.1046/j.1528-1157.2001.12301.x.
Erdö, F., Denes, L., De Lange, E., 2017. Age-associated physiological and pathological
changes at the blood-brain barrier: a review. J. Cereb. Blood Flow Metab. 37. https://
doi.org/10.1177/0271678X16679420.
Feldmann, M., Asselin, M.-C., Liu, J., Wang, S., McMahon, A., Anton-Rodriguez, J.,
Walker, M., Symms, M., Brown, G., Hinz, R., Matthews, J., Bauer, M., Langer, O.,
Thom, M., Jones, T., Vollmar, C., Duncan, J.S., Sisodiya, S.M., Koepp, M.J., 2013. P-
glycoprotein expression and function in patients with temporal lobe epilepsy: a case-
control study. Lancet Neurol. 12, 777–785. https://doi.org/10.1016/S1474-4422(13)
70109-1.
Gibson, C.J., Hossain, M.M., Richardson, J.R., Aleksunes, L.M., 2012. Inﬂammatory
regulation of ATP binding cassette eﬄux transporter expression and function in mi-
croglia. J. Pharmacol. Exp. Ther. 343, 650–660. https://doi.org/10.1124/jpet.112.
196543.
Hammarlund-Udenaes, M., Paalzow, L.K., De Lange, E.C.M., 1997. Drug equilibration
across the blood-brain barrier - pharmacokinetic considerations based on the mi-
crodialysis method. Pharm. Res. 14. https://doi.org/10.1023/A:1012080106490.
Hooker, A.C., Staatz, C.E., Karlsson, M.O., 2007. Conditional weighted residuals
(CWRES): a model diagnostic for the FOCE method. Pharm. Res. 24, 2187–2197.
https://doi.org/10.1007/s11095-007-9361-x.
Jing, X., Liu, X.X., Wen, T., Xie, S., Yao, D., Liu, X.X., Wang, G., Xie, L., 2010. Combined
eﬀects of epileptic seizure and phenobarbital induced overexpression of P-glyco-
protein in brain of chemically kindled rats: research paper. Br. J. Pharmacol. 159,
1511–1522. https://doi.org/10.1111/j.1476-5381.2009.00634.x.
Jonsson, E.N., Karlsson, M.O., 1998. Xpose - An S-PLUS based population pharmacoki-
netic/pharmacodynamic model building aid for NONMEM. Comput. Methods Prog.
Biomed. 58, 51–64. https://doi.org/10.1016/S0169-2607(98)00067-4.
Kervezee, L., Hartman, R., Van Den Berg, D.-J., Shimizu, S., Emoto-Yamamoto, Y., Meijer,
J.H., De Lange, E.C.M., 2014. Diurnal variation in P-glycoprotein-mediated transport
and cerebrospinal ﬂuid turnover in the brain. AAPS J. 16. https://doi.org/10.1208/
s12248-014-9625-4.
Kuteykin-Teplyakov, K., Brandt, C., Hoﬀmann, K., Löscher, W., 2009. Complex time-de-
pendent alterations in the brain expression of diﬀerent drug eﬄux transporter genes
after status epilepticus. Epilepsia 50, 887–897. https://doi.org/10.1111/j.1528-
1167.2008.01916.x.
Lee, G., Dallas, S., Hong, M., Bendayan, R., 2001. Drug transporters in the central nervous
system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53,
569–596 (https://doi.org/Animals Blood-Brain Barrier/*physiology Central Nervous
System/*metabolism Humans Membrane Transport Proteins/*metabolism
Neuroglia/metabolism Neurons/metabolism Pharmaceutical Preparations/*metabo-
lism Research Support, Non-U.S. Gov't).
Marchi, N., Hallene, K.L., Kight, K.M., Cucullo, L., Moddel, G., Bingaman, W., Dini, G.,
Vezzani, A., Janigro, D., 2004. Signiﬁcance of MDR1 and multiple drug resistance in
refractory human epileptic brain. BMC Med. 2 (37). https://doi.org/10.1186/1741-
7015-2-37.
Marchi, N., Banjara, M., Janigro, D., 2016. Blood – brain barrier, bulk ﬂow, and inter-
stitial clearance in epilepsy. J. Neurosci. Methods 260, 118–124. https://doi.org/10.
1016/j.jneumeth.2015.06.011.
Micuda, S., Brcakova, E., Fuksa, L., Cermanova, J., Osterreicher, J., Hroch, M., Mokry, J.,
Pejchal, J., Martinkova, J., Staud, F., 2008. P-glycoprotein function and expression
during obstructive cholestasis in rats. Eur. J. Gastroenterol. Hepatol. 20, 404–412.
https://doi.org/10.1097/MEG.0b013e3282f471bf.
Mistry, P., Stewart, A.J., Dangerﬁeld, W., Okiji, S., Liddle, C., Bootle, D., Plumb, J.A.,
Templeton, D., Charlton, P., 2001. In vitro and in vivo reversal of P-glycoprotein-
mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 61
(2), 749–758.
Moghaddam, B., Bunney, B.S., 1989. Ionic composition of microdialysis perfusing solu-
tion alters the pharmacological responsiveness and basal outﬂow of striatal dopa-
mine. J. Neurochem. 53, 652–654. https://doi.org/10.1111/j.1471-4159.1989.
tb07383.x.
Müllauer, J., Kuntner, C., Bauer, M., Bankstahl, J.P., Müller, M., Voskuyl, R.A., Langer, O.,
Syvänen, S., 2012. Pharmacokinetic modeling of P-glycoprotein function at the rat
and human blood-brain barriers studied with (R)-[11C]verapamil positron emission
tomography. EJNMMI Res. 2, 1–15. https://doi.org/10.1186/2191-219X-2-58.
Racine, R.J., 1972. Modiﬁcation of seizure activity by electrical stimulation: II. Motor
seizure. Electroencephalogr. Clin. Neurophysiol. 32, 281–294. https://doi.org/10.
1016/0013-4694(72)90177-0.
Ransohoﬀ, R.M., Liu, L., Cardona, A.E., 2007. Chemokines and chemokine receptors:
multipurpose players in neuroinﬂammation. Int. Rev. Neurobiol. 82, 187–204.
https://doi.org/10.1016/S0074-7742(07)82010-1.
Ronaldson, P.T., Persidsky, Y., Bendayan, R., 2008. Regulation of ABC membrane
transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection.
Glia 56, 1711–1735. https://doi.org/10.1002/glia.20725.
Seegers, U., Potschka, H., Löscher, W., 2002. Transient increase of P-glycoprotein ex-
pression in endothelium and parenchyma of limbic brain regions in the kainate model
of temporal lobe epilepsy. Epilepsy Res. 51, 257–268. https://doi.org/10.1016/
S0920-1211(02)00156-0.
Sugihara, N., Furuno, K., Kita, N., Murakami, T., Yata, N., 1993. The inﬂuence of in-
creased plasma protein binding on the disposition of quinidine in turpentine-treated
rats. Biol. Pharm. Bull. 16, 63–67. https://doi.org/10.1248/bpb.16.63.
Syvänen, S., Luurtsema, G., Molthoﬀ, C.F., Windhorst, A.D., Huisman, M.C., Lammertsma,
A.A., Voskuyl, R.A., de Lange, E.C., 2011. (R)-[11C]verapamil PET studies to assess
changes in P-glycoprotein expression and functionality in rat blood-brain barrier after
exposure to kainate-induced status epilepticus. BMC Med. Imaging 11. https://doi.
org/10.1186/1471-2342-11-1.
Syvänen, S., Labots, M., Tagawa, Y., Eriksson, J., Windhorst, A.D., Lammertsma, A.A., De
Lange, E.C., Voskuyl, R.A., 2012a. Altered GABA(A) receptor density and unaltered
blood brain barrier transport in a kainate model of epilepsy: an in vivo study using
11C-ﬂumazenil and PET. J. Nucl. Med. 53 (12), 1974–1983. https://doi.org/10.
2967/jnumed.112.104588.
Syvänen, S., Schenke, M., Van Den Berg, D.-J., Voskuyl, R.A., De Lange, E.C., 2012b.
Alteration in P-glycoprotein functionality aﬀects intrabrain distribution of quinidine
more than brain entry-a study in rats subjected to status epilepticus by kainate. AAPS
J. 14. https://doi.org/10.1208/s12248-011-9318-1.
Syvänen, S., Russmann, V., Verbeek, J., Eriksson, J., Labots, M., Zellinger, C., Seeger, N.,
Schuit, R., Rongen, M., van Kooij, R., Windhorst, A.D., Lammertsma, A.A., de Lange,
E.C., Voskuyl, R.A., Koepp, M., Potschka, H., 2013. [11C]quinidine and [11C]lani-
quidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-
responsiveness. Nucl. Med. Biol. 40. https://doi.org/10.1016/j.nucmedbio.2013.05.
008.
Tishler, D.M., Weinberg, K.I., Hinton, D.R., Barbaro, N., Annett, G.M., Raﬀel, C., 1995.
MDR1 gene expression in brain of patients with medically intractable epilepsy.
Epilepsia 36, 1–6. https://doi.org/10.1111/j.1528-1157.1995.tb01657.x.
Uchida, Y., Ohtsuki, S., Terasaki, T., 2014. Pharmacoproteomics-based reconstruction of
in vivo P-glycoprotein function at blood-brain barrier and brain distribution of sub-
strate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and
phenytoin treatment models. Drug Metab. Dispos. 42, 1719–1726. https://doi.org/
E.C.M. De Lange et al. European Journal of Pharmaceutical Sciences 124 (2018) 61–70
69
10.1124/dmd.114.059055.
Van Vliet, E., Aronica, E., Redeker, S., Marchi, N., Rizzi, M., Vezzani, A., Gorter, J., 2004.
Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the
parahippocampal cortex of chronic epileptic rats. Epilepsy Res. 60, 203–213. https://
doi.org/10.1016/j.eplepsyres.2004.06.005.
van Vliet, E.A., van Schaik, R., Edelbroek, P.M., Voskuyl, R.A., Redeker, S., Aronica, E.,
Wadman, W.J., Gorter, J.A., 2007. Region-speciﬁc overexpression of P-glycoprotein
at the blood-brain barrier aﬀects brain uptake of phenytoin in epileptic rats. J.
Pharmacol. Exp. Ther. 322, 141–147. https://doi.org/10.1124/jpet.107.121178.
Volk, H.A., Loscher, W., 2005. Multidrug resistance in epilepsy: rats with drug-resistant
seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with
drug-responsive seizures. Brain 128, 1358–1368.
Volk, H.A., Burkhardt, K., Potschka, H., Chen, J., Becker, A., Löscher, W., 2004. Neuronal
expression of the drug eﬄux transporter P-glycoprotein in the rat hippocampus after
limbic seizures. Neuroscience 123 (3), 751–759. https://doi.org/10.1016/j.
neuroscience.2003.10.012.
Watari, N., Wakamatsu, A., Kaneniwa, N., 1989. Comparison of disposition parameters of
quinidine and quinine in the rat. Aust. J. Pharm. 12, 608–615. https://doi.org/10.
1248/bpb1978.12.608.
Westerhout, J., Ploeger, B., Smeets, J., Danhof, M., Lange, E.C.M., 2012. Physiologically-
based pharmacokinetic modeling to investigate regional brain distribution kinetics in
rats. AAPS J. 14 (3), 543–553.
Westerhout, J., Smeets, J., Danhof, M., De Lange, E.C.M., 2013. The impact of P-gp
functionality on non-steady state relationships between CSF and brain extracellular
ﬂuid. J. Pharmacokinet. Pharmacodyn. 40 (3), 327–342. https://doi.org/10.1007/
s10928-013-9314-4.
Wilkins, J.J., 2005. NONMEMory: a run management tool for NONMEM. Comput.
Methods Prog. Biomed. 78, 259–267. https://doi.org/10.1016/j.cmpb.2005.02.003.
Yamamoto, Y., Välitalo, P.A., Wong, Y.C., Huntjens, D.R., Proost, J.H., Vermeulen, A.,
Krauwinkel, W., Beukers, M.W., Kokki, H., Kokki, M., Danhof, M., van Hasselt, J.G.C.,
de Lange, E.C.M., 2018. Prediction of human CNS pharmacokinetics using a phy-
siologically-based pharmacokinetic modeling approach. Eur. J. Pharm. Sci. 112.
https://doi.org/10.1016/j.ejps.2017.11.011.
Zhang, L., Ong, W.Y., Lee, T., 1999. Induction of P-glycoprotein expression in astrocytes
following intracerebroventricular kainate injections. Exp. Brain Res. 126, 509–516.
https://doi.org/10.1007/s002210050759.
E.C.M. De Lange et al. European Journal of Pharmaceutical Sciences 124 (2018) 61–70
70
